Visual/CNS effects of quality ivermectin doses 0.4m/kg+ – providers experience?
-
Visual/CNS effects of quality ivermectin doses 0.4m/kg+ – providers experience?
I would like to know if other prescribers have heard their patients reporting this?
I would also like to ask if those studying or publishing ivermectin protocols (cancer, long covid) if their recommended high doses might be because their patient are getting POOR QUALITY ivermectin and need the higher doses to see effect? We are finding that if patients source their ivermectin pure from a reputable source, they usually cannot tolerate doses of even 0.6mg/kg/day due to ocular (presumed CNS) effect, that seems to reverse when stopped or lowered dose. Would appreciate if Dr Makis or Dr McCullough would have the time to respond: [email protected].
We have a quality compounding pharmacy in Mt Vernon WA for ivermectin – they only use inert plant tissue for the compounding (in all their meds) and have a certificate of analysis studies of their sourced ivermectin – it is a PURE form. EVERY patient we have prescribed a higher dose (for some it starts at 0.4mg/kg/day for others at 0.6mg/kg/day) they get a CNS effect of ocular distrubance that presents as a “strobe-like” visual effect. It is overall very bright white light or dulled colors, flashes like a stroke between dark and bright vision. Starts a few hours after consumption, less noticeable if taking before sleep, can last for 12+ hours. Resolves at lower doses or discontinuing. I have read this can happen (some case studies) at higher doses. I did not (previously) consider 0.4mg/kg a higher dose, but compared to published parasite protocol it is.
We want to use this aggressively for our patients who have advanced cancer, but are finding we cannot follow any of the protocols due to this effect. For those that tolerate 0.4mg/kg/day we are staying there, for those that can’t we are lowering to 0.2mg/kg/day.
We have one patient with a rare to treat advanced metastatic cancer that appears to be responding, about 4 months in. It is likely a combination of this and the AVM0703 we started around the same time. Will plan to submit for publication as a case study if progress continues.
Sincerely, Renay Fredette, MD – Renova.Health
Log in to reply.
